Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INT101
- Development stage
- Phase 1
- Lead developer
- InThera
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
INT101 is an investigational trivalent recombinant virus-like particle (VLP) vaccine developed by InThera for the prevention of acute gastroenteritis caused by norovirus infection. The vaccine is produced using a proprietary E. coli expression system that enables high-purity, uniform VLP self-assembly in vitro, avoiding insect cell-derived impurities. It contains VLP antigens representing three epidemiologically significant norovirus genotypes: GII.3, GII.4, and GII.17. INT101 is administered via intramuscular injection and is designed to elicit robust protective humoral and mucosal immune responses against norovirus. It is currently in Phase 1 clinical development in healthy adults.
02
Targets
JCV (John Cunningham virus)
Beyond the preview
Go deeper on INT101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INT101.